Medicine

Molecular profiling of BRAF-V600E-mutant metastatic intestines cancer in the phase\u00e2 $ 3 LIGHTHOUSE CRC test

.Competing rate of interests.S.K.: Sell and also Various Other Possession Passions: Iylon, Lutris, MolecularMatch, Navire. Consulting or Advisory Job: AbbVie, Amal Rehabs, AstraZeneca/MedImmune, Bayer Health, Bicara Rehabs, Boehringer Ingelheim, Boston Ma Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Endeavor BioMedicines, Fire Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Medical Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Pharmaceuticals, Lilly, Lutris, Merck, Mirati Therapies, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Therapeutics, Servier, Xilis. Research Study Financing: Amgen (Inst), Range BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Health (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Work: Previously Pfizer. Sell as well as Various Other Possession Enthusiasms: Pfizer. J.P.: Work: In The Past Pfizer. Supply and also Other Ownership Claims: Pfizer. F.C.: Consulting or even Advisory Role: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Analysis Financing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or even Advisory Duty: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Investigation Backing: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or Advisory Duty: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Drug, Terumo. H.S.W.: Consulting or Advisory Role: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Rehabs, Erytech Pharma, Incyte, Merck KGaA, Oaktree Life Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, Shire, Sirtex Medical, Takeda (Hutchinson Medication), Zymeworks. Investigation Financing: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Pharmaceutical, Sumitomo Corp., Takeda. Research Funding: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Health And Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Drug (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Drug (Inst). H.S.: Work: Pfizer. Stock and also Various Other Ownership Stakes: Pfizer. X.Z.: Job: Pfizer. Assets and Other Ownership Stakes: Pfizer. Patents, Nobilities, Various Other Trademark: Johns Hopkins University. P.H.: Employment: Pfizer. Stock and Other Ownership Interests: Pfizer. T.X.: Employment: Pfizer. Inventory as well as Various Other Possession Stakes: Pfizer. R.Y.: Consulting or even Advisory Duty: Array BioPharma/Pfizer, Mirati Therapeutics, Zai Laboratory, Amgen. Study Backing: Array BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapy (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or even Advisory Duty: Selection BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapies, MSD, NeoPhore, Novartis, Ona Therapeutics, Orion Medical, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Therapy, Seagen Inc., Servier, Taiho Drug, Tessa Rehab, TheraMyc. Various Other Relationship: Amgen, Assortment Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Study UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de Los Angeles Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Opposite el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Wellness KGaA, MJH Life Sciences, MSD, Merus, Mirati, Novartis, Oniria Therapies, PeerView Principle for Medical Education, Pfizer, PharmaMar, Physicansu00e2 $ Education Source, Sanofi-Aventis, Servier, Taiho Drug.